دورية أكاديمية
أعرض في EDS

Molecular and translational biology of the blood-based VeriStrat® proteomic test used in cancer immunotherapy treatment guidance.

التفاصيل البيبلوغرافية
العنوان: Molecular and translational biology of the blood-based VeriStrat® proteomic test used in cancer immunotherapy treatment guidance.
المؤلفون: Koc MA; Biodesix Inc., 2970 Wilderness Place Suite 100, Boulder, CO 80301, United States., Wiles TA; Biodesix Inc., 2970 Wilderness Place Suite 100, Boulder, CO 80301, United States., Weinhold DC; Biodesix Inc., 2970 Wilderness Place Suite 100, Boulder, CO 80301, United States., Rightmyer S; Biodesix Inc., 2970 Wilderness Place Suite 100, Boulder, CO 80301, United States., Weaver AL; Biodesix Inc., 2970 Wilderness Place Suite 100, Boulder, CO 80301, United States., McDowell CT; Biodesix Inc., 2970 Wilderness Place Suite 100, Boulder, CO 80301, United States., Roder J; Biodesix Inc., 2970 Wilderness Place Suite 100, Boulder, CO 80301, United States., Asmellash S; Biodesix Inc., 2970 Wilderness Place Suite 100, Boulder, CO 80301, United States., Pestano GA; Biodesix Inc., 2970 Wilderness Place Suite 100, Boulder, CO 80301, United States., Roder H; Biodesix Inc., 2970 Wilderness Place Suite 100, Boulder, CO 80301, United States., Georgantas Iii RW; Biodesix Inc., 2970 Wilderness Place Suite 100, Boulder, CO 80301, United States.
المصدر: Journal of mass spectrometry and advances in the clinical lab [J Mass Spectrom Adv Clin Lab] 2023 Nov 20; Vol. 30, pp. 51-60. Date of Electronic Publication: 2023 Nov 20 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101776811 Publication Model: eCollection Cited Medium: Internet ISSN: 2667-145X (Electronic) Linking ISSN: 2667145X NLM ISO Abbreviation: J Mass Spectrom Adv Clin Lab Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Amsterdam] : Elsevier B.V., [2021]-
مستخلص: Introduction: The VeriStrat® test (VS) is a blood-based assay that predicts a patient's response to therapy by analyzing eight features in a spectrum obtained from matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) analysis of human serum and plasma. In a recent analysis of the INSIGHT clinical trial (NCT03289780), it was found that the VS labels, VS Good and VS Poor, can effectively predict the responsiveness of non-small cell lung cancer (NSCLC) patients to immune checkpoint inhibitor (ICI) therapy. However, while VS measures the intensities of spectral features using MALDI-TOF analysis, the specific proteoforms underlying these features have not been comprehensively identified.
Objectives: The objective of this study was to identify the proteoforms that are measured by VS.
Methods: To resolve the features obtained from the low-resolution MALDI-TOF procedure used to acquire mass spectra for VS DeepMALDI® analysis of serum was employed. This technique allowed for the identification of finer peaks within these features. Additionally, a combination of reversed-phase fractionation and liquid chromatography-tandem mass spectrometry (LC-MS/MS) was then used to identify the proteoforms associated with these peaks.
Results: The analysis revealed that the primary constituents of the spectrum measured by VS are serum amyloid A1, serum amyloid A2, serum amyloid A4, C-reactive protein, and beta-2 microglobulin.
Conclusion: Proteoforms involved in host immunity were identified as significant components of these features. This newly acquired information improves our understanding of how VS can accurately predict patient response to therapy. It opens up additional studies that can expand our understanding even further.
Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: All authors are current and/or former employees of and have or had stock options in Biodesix, Inc. Heinrich Roder, Joanna Roder, and Senait Asmellash are inventors on patents describing DeepMALDI, assigned to Biodesix, Inc.
(© 2023 THE AUTHORS.)
References: J Immunother Cancer. 2021 Oct;9(10):. (PMID: 34706885)
Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):10852-7. (PMID: 16043703)
Transl Cancer Res. 2021 May;10(5):2255-2264. (PMID: 35116543)
BMC Cancer. 2018 Mar 20;18(1):310. (PMID: 29558888)
Cancer Immunol Immunother. 2021 Jun;70(6):1583-1592. (PMID: 33231726)
Exp Ther Med. 2022 Jul 05;24(3):557. (PMID: 35978940)
Lancet Oncol. 2014 Jun;15(7):713-21. (PMID: 24831979)
PLoS One. 2020 Mar 26;15(3):e0230798. (PMID: 32214370)
Expert Rev Respir Med. 2014 Feb;8(1):1-4. (PMID: 24308656)
Biomarkers. 2016 Dec;21(8):743-751. (PMID: 27308834)
PLoS One. 2019 Dec 9;14(12):e0226012. (PMID: 31815946)
FEBS Lett. 2003 Feb 27;537(1-3):166-70. (PMID: 12606051)
Nat Rev Neurosci. 2013 May;14(5):365-76. (PMID: 23571845)
Nat Commun. 2017 Oct 26;8(1):1136. (PMID: 29070816)
Cancer Med. 2014 Jun;3(3):572-9. (PMID: 24574334)
Cancer Cell Int. 2019 Mar 20;19:62. (PMID: 30930691)
Molecules. 2022 Feb 01;27(3):. (PMID: 35164262)
Med Pediatr Oncol. 1980;8(4):323-34. (PMID: 6161299)
J Immunother Cancer. 2020 Apr;8(1):. (PMID: 32303612)
Curr Med Res Opin. 2020 Sep;36(9):1497-1505. (PMID: 32615813)
Anal Chem. 2008 Aug 1;80(15):5713-20. (PMID: 18613646)
Cell Syst. 2018 Oct 24;7(4):412-421.e5. (PMID: 30172843)
PLoS One. 2015 Jan 21;10(1):e0115320. (PMID: 25607823)
J Am Soc Mass Spectrom. 2019 Jul;30(7):1174-1178. (PMID: 31044356)
J Proteome Res. 2006 Jul;5(7):1682-7. (PMID: 16823976)
Front Oncol. 2022 Jan 31;12:772076. (PMID: 35174082)
Proteomics. 2019 May;19(10):e1800361. (PMID: 31050378)
Biol Chem. 2009 Aug;390(8):783-94. (PMID: 19426129)
J Proteomics. 2012 Dec 5;76 Spec No.:91-101. (PMID: 22771314)
Hematol Oncol. 1984 Oct-Dec;2(4):391-401. (PMID: 6396193)
Nucleic Acids Res. 2020 Jan 8;48(D1):D328-D334. (PMID: 31724716)
Anal Chem. 2014 Jun 17;86(12):5807-14. (PMID: 24848523)
J Transl Med. 2009 Nov 30;7:102. (PMID: 19948067)
Clin Cancer Res. 2012 May 1;18(9):2417-9. (PMID: 22442060)
Clin Cancer Res. 2007 Apr 1;13(7):1979-86. (PMID: 17404077)
J Biol Chem. 1979 Jan 25;254(2):489-502. (PMID: 762075)
Clin Cancer Res. 2012 May 1;18(9):2695-703. (PMID: 22351685)
Cancer Epidemiol Biomarkers Prev. 2016 Apr;25(4):657-64. (PMID: 26908438)
Mayo Clin Proc. 1994 Sep;69(9):895-902. (PMID: 8065197)
Anal Biochem. 2001 Feb 1;289(1):26-35. (PMID: 11161291)
PLoS One. 2015 Dec 30;10(12):e0143080. (PMID: 26717416)
J Natl Cancer Inst. 2007 Jun 6;99(11):838-46. (PMID: 17551144)
Transl Lung Cancer Res. 2020 Aug;9(4):1015-1028. (PMID: 32953481)
Curr Hematol Malig Rep. 2016 Feb;11(1):37-42. (PMID: 26748932)
Eur J Immunol. 2014 Jun;44(6):1672-84. (PMID: 24659444)
Cancer. 2010 Apr 1;116(7):1638-45. (PMID: 20143445)
Cancers (Basel). 2021 Jun 22;13(13):. (PMID: 34206321)
Immunology. 2021 Nov;164(3):507-523. (PMID: 34115389)
Front Immunol. 2022 Feb 08;13:827788. (PMID: 35211122)
Anal Chem. 2001 Jul 15;73(14):3294-9. (PMID: 11476228)
Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):358-65. (PMID: 20086114)
J Thorac Oncol. 2012 Nov;7(11):1653-60. (PMID: 23059783)
J Exp Med. 2010 Jul 5;207(7):1453-64. (PMID: 20530204)
Adv Intern Med. 1982;27:345-72. (PMID: 7041546)
Hematol Oncol. 2017 Dec;35(4):440-446. (PMID: 27238634)
Anal Chem. 2008 Aug 15;80(16):6159-67. (PMID: 18642877)
Front Immunol. 2020 Nov 19;11:595835. (PMID: 33324413)
Nucleic Acids Res. 2020 Jan 8;48(D1):D1145-D1152. (PMID: 31686107)
Clin Mass Spectrom. 2020 Sep 09;18:13-26. (PMID: 34820522)
Mol Med. 2018 Aug 30;24(1):46. (PMID: 30165816)
Eur J Cancer. 2019 Oct;120:86-96. (PMID: 31499384)
Nat Commun. 2019 Apr 23;10(1):1921. (PMID: 31015469)
Stat Methods Med Res. 2021 Mar;30(3):687-701. (PMID: 33228480)
Oncogene. 2008 Oct 6;27(45):5869-85. (PMID: 18836468)
Front Immunol. 2018 Jun 07;9:1302. (PMID: 29951057)
Mol Cell Proteomics. 2007 Jul;6(7):1183-7. (PMID: 17468123)
J Natl Cancer Inst. 1996 Jan 17;88(2):100-8. (PMID: 8537970)
Br J Cancer. 2006 Nov 20;95(10):1379-83. (PMID: 17060939)
BMC Cancer. 2016 Nov 3;16(1):836. (PMID: 27809798)
فهرسة مساهمة: Keywords: Immunotherapy; MALDI; Mass spectrometry; Prognostic; Top-down proteomics
تواريخ الأحداث: Date Created: 20231211 Latest Revision: 20231211
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC10709509
DOI: 10.1016/j.jmsacl.2023.11.001
PMID: 38074293
قاعدة البيانات: MEDLINE
الوصف
تدمد:2667-145X
DOI:10.1016/j.jmsacl.2023.11.001